Progress in myoblast transplantation: A potential treatment of dystrophies

Microscopy Research and Technique

Volumn 48, Issue 3-4, 2000, Pages 213-222

  Skuk, Daniel ^a   Tremblay, Jacques P ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cell transplantation; Muscle; Myopathies

Indexed keywords

CELLS; CLINICAL RESEARCH; CYTOLOGY; MAMMALS;

ANIMAL MODEL; CELL TRANSPLANTATION; CLINICAL TRIAL; EXPERIMENTAL APPROACHES; GENETICALLY MODIFIED; MUSCLE DISEASE; MYOBLAST TRANSPLANTATION; MYOBLASTS; MYOGENIC CELLS; MYOPATHY;

MUSCLE;

TACROLIMUS;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; MUSCLE TRANSPLANTATION; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALIA;

EID: 0033950086     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0029(20000201/15)48:3/4<213::AID-JEMT9>3.0.CO;2-Z     Document Type: Article

References (132)

1. Alameddine HS, Louboutin JP, Dehaupas M, Sébille A, Fardeau M. 1994. Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant 3:3-14.
2. Appleyard ST, Dunn MJ, Dubowitz V, Rose ML. 1985. Increased expression of HLA ABC class I antigens by muscle fibers in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1:361-363.
3. Arcila ME, Ameredes BT, DeRosimo JF, Washabaugh CH, Yang J, Johnson PC, Ontell M 1997. Mass and functional capacity of regenerating muscle is enhanced by myoblast transfer. J Neurobiol 33:185-198.
4. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. 1994. Quantitative studies of efficacy of myoblast transplantation. Muscle Nerve 4(Suppl):261.
5. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. 1999. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 144:1113-1122.
6. Birmingham K. 1997. Controversial muscular dystrophy therapy goes to court. Nat Med 3:1058.
7. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP. Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352.
8. Bohl D, Heard JM. 1997. Modulation of erythropoietin delivery from engineered muscles in mice. Hum. Gene Ther 8:195-204.
9. Boulanger A, Asselin I, Roy R, Tremblay JP. 1997. Role of non-major histocompatibility complex antigens in the rejection of transplanted myoblasts. Transplantation 63:893-899.
10. Brussee V, Tardif F, Tremblay JP. 1997. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromusc Disord 7:487-492.
11. Brussee V, Merly F, Tardif F, Tremblay JP. 1998. Normal myoblast implantation in mdx mice prevents muscle damage by exercise. Biochem Biophys Res Commun 250:321-327.
12. Cacciarelli TV, Green M, Jaffe R, Mazariegos GV. Jain A, Fung JJ, Reyes J. 1998. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 66:1047-1052.
13. Campion DR. 1984. The muscle satellite cell: a review. Int Rev Cytol 87:225-251.
14. Carlson BM, Faulkner JA. 1983. The regeneration of skeletal muscle fibers following injury: a review. Med Sci Sports Exerc 15:187-198.
15. Cifuentes-Diaz C, Delaporte C, Dautréaux B, Charron D, Fardeau M. 1992. Class II MHC antigens in normal human skeletal muscle. Muscle Nerve 15:295-302.
16. Cooper BJ. 1989. Animal models of Duchenne and Becker muscular dystrophy. Br Med Bull 45:703-718.
17. Day CS, Kasemkijwattana C, Menetrey J, Floyd SS. Jr, Booth D, Moreland MS, Fu FH, Huard J. 1997. Myoblast-mediated gene transfer to the joint. J Orthop Res 15:894-903.
18. Deglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, Aebischer P 1996. Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum. Gene Ther 7:2135-2146.
19. Deschênes I, Chahine M, Tremblay J, Paulin D, Puymirat J. 1997. Increase in the proliferative capacity of human myoblasts by using the T antigen under the vimentin promoter control. Muscle Nerve 97;20:437-445.
20. Dhawan J, Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau HM. 1991. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254:1509-1512.
21. Dhawan J, Rando TA, Elson SE, Lee F, Stanley ER, Blau HM. 1996. Myoblast-mediated expression of colony stimulating factor-1 (CSF-1. in the cytokine-deficient op/op mouse. Somat Cell Mol Genet 22:363-381.
22. Emslie-SmithAM, Arahata K, Engel AG. 1989. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20:224-231.
23. Ennis BW, Matrilisian LM. 1994. Matrix degrading metalloproteinases. J Neurooncol 18:105-109.
24. Fan Y, Beilharz MW, Grounds M. 1996a. A potential alternative strategy for myoblast transfer therapy: the use of sliced muscle grafts. Cell Transplant 5:421-429.
25. Fan Y, Maley M, Beilharz M, Grounds M. 1996b. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve 19:853-860.
26. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F. 1998. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279:1528-1530.
27. Floyd SS, Clemens PR, Ontell MR, Kochanek S, Day CS, Yang J, Hauschka SD, Balkir L, Morgan J, Moreland MS, Feero GW, Epperly M, Huard J. 1998. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 5:19-30.
28. Gill RG, WoIf L. 1995. Immunobiology of cellular transplantation. Cell Transplant 4:361-370.
29. Gross JG, Morgan JE. 1999. Muscle precursor cells injected into irradiated mdx mouse muscle persist after serial injury. Muscle Nerve 22:174-185.
30. Grounds MD. 1996. Commentary on the present state of knowledge for myoblast transfer therapy. Cell Transplant 5:431-433.
31. Guérette B, Asselin I, Vilquin JT, Roy R, Tremblay JP. 1994. Lymphocyte infiltration following allo and xeno myoblast transplantation in mice. Transpl Proc 26:4061-4062.
32. Guérette B, Asselin I, Roy R, Tremblay JP. 1995a. Lymphocyte infiltration following allo and xeno myoblast transplantation in mdx mice. Muscle Nerve, 18:39-51.
33. Guérette B, Roy R, Tremblay M, Asselin I, Kinoshita I, Tremblay JP. 1995b. Increased granzyme B mRNA following alloincompatible myoblast transplantation. Transplantation 60:1011-1016.
34. Guérette B, Tremblay G, Vilquin J-T, Asselin I, Roy R, Tremblay JP. 1996. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. Muscle Nerve 19:829-835.
35. Guérette B, Asselin I, Skuk D, Entman M, Tremblay JP. 1997a. Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. Cell Transplant 6:101-107.
36. Guérette B, Célestin F, Skuk D, Entman M, Tardif F, Asselin I, Roy B, Goulet M, Huard C, Tremblay JP. 1997b. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J Immunol 159:2522-2531.
37. Guérette B, Wood K, Roy R, Tremblay JP. 1997c. Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig. Transplant Proc 29:1932-1934.
38. Gussoni E, Pavlath GK, Lanctot V.K, Sharma RG, Miller L, Steinman L, Blau HM. 1992. Normal dystrophin transcripts detected in DMD patients after myoblast transplantation. Nature 356:435-438.
39. Gussoni E, Blau HM, Kunkel LM. 1997. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3:970-977.
40. Hamamori Y, Samal B, Tian J, Kedes L 1994. Persistent erythropoiesis bv myoblast transfer of erythropoietin cDNA. Hum Gene Ther 5:1349-1356.
41. Hamamori Y, Samal B, Tian J, Kedes L. 1995. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 95:1808-1813.
42. Hoffman EP, Brown RH. Jr, Kunkel LM. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919-928.
43. Hofmann A, Blau HM. 1997. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts. Somat Cell Mol Genet 23:249-257.
44. Huard C, Moisset P-A, Dicaire A, Merly F, Tardif F, Asselin I, Tremblay JP. 1998. Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. Biochem Biophys Res Commun 248:648-654.
45. Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, Albert N, Richards CL, Lemieux B, Tremblay JP. 1992. Human myoblast transplantation: preliminary results of four cases. Muscle Nerve 15:550-560.
46. Huard J, Acsadi A, Jani B, Massie B, Karpati G. 1994a. Gene transfer into skeletal muscles by isogenic myoblasts. Hum Gene Ther 5:949.
47. Huard J, Roy R, Guérette B, Verreault S, Tremblay G, Tremblay JP. 1994b. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve 17:224-234.
48. Huard J, Verreault S, Roy R, Tremblay JP. 1994c. High efficacy of muscle regeneration following human myoblast transplantation in SCID mice. J Clin Invest 93:586-599.
49. Irintchev A, Zweyer M, Wernig A. 1995. Cellular and molecular reactions in mouse muscles after myoblast implantation. J Neurocytol 24:319-331.
50. Irintchev A, Langer M, Zweyer M, Theisen R, Wernig A. 1997. Functional improvement of damaged adult mouse muscle by implantation of primary myoblasts. J Physiol (Lond) 500.3:775-785.
51. Irintchev A, Rosenblatt JD, Cullen MJ, Zweyer M, Wernig A. 1998. Ectopic skeletal muscles derived from myoblasts implanted under the skin. J Cell Sci 111:3287-3297.
52. Ito H, Hallauer PL, Hastings KE.M, Tremblay JP. 1998a. Prior culture with concanavalin A increases intramuscular migration of transplanted myoblast. Muscle Nerve 21:291-297
53. Ito H, Vilquin J-T, Skuk D, Roy B, Goulet M, Lille S, Dugré FJ, Asselin I, Roy R, Fardeau M, Tremblay JP. 1998b. Myoblast transplantation in non-dystrophic dog. Neuromusc Disord 8:95-110
54. Kakulas BA. 1997. Problems and potential for gene therapy in Duchenne muscular dystrophy. Neuromusc Disord 7:319-324.
55. Karpati G, Pouilot Y, Carpenter S. 1988. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23:64-72.
56. Karpati G, Ajdukovic D, Arnold D, Glendhill RB, Guttmann R, Holland P, Koch PA, Shoubridge E, Spence D, Vanasse M, Watters GV, Abrahamowicz M, Duff C, Worton RG. 1993. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 34:8-17.
57. Kinoshita I, Vilquin J-T, Guérette B, Asselin I, Roy R, Tremblay JP. 1994. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17:1407-1415.
58. Kinoshita I, Vilquin J-T, Gravel C, Roy R, Tremblay JP. 1995a. Myoblast allotransplantation in primates. Muscle Nerve 18:1217-1218.
59. Kinoshita I, Vilquin J-T, Tremblay JP. 1995b. Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice. Muscle Nerve 18:834-841.
60. Kinoshita I, Roy R, Dugré FJ, Gravel C, Vilquin J-T, Roy B, Goulet M, Asselin I, Tremblay JP. 1996. Myoblast transplantation in monkeys: control of immune response by FK506. J Neuropathol Exp Neurol 55:687-697.
61. Klintmalm GB, Gonwa TA. 1995. Nephrotoxicity associated with cyclosporine and FK506. Liver Transpl Surg 1(5 Suppl 1):11-19.
62. Koh GY, Klug MG, Soonpaa MH, Field LJ. 1993. Differentiation and long-term survival of C2C12 myoblast grafts in heart. J Clin Invest 92:1548-1554.
63. Kornegay JN, Sharp NJ.H, Bartlett RJ, Van Camp SD, Burt CT, Hung WY, Kwock L, Roses AD. 1990. Golden retriever muscular dystrophy: monitoring for success. In: Eastwood AB, Karpati G, Griggs R, editors. Myoblast transfer therapy. New York: Plenum Publishing Corp. p 267-272.
64. Labrecque C, Roy R, Tremblay JP. 1992. Immune reactions after myoblast transplantation in mouse models. Transpl Proc 24:2889-2892.
65. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109-112.
66. Law PK, Goodwin TG, Wang MG. 1988. Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve 11:525-533.
67. Law PK, Goodwin TG, Fang Q, Deering MB, Duggirala V, Larkin C, Florendo JA, Kirby DS, Li HJ, Chen M, Cornett J, Li LM, Shirzad A, Quinley T, Yoo TJ, Holcomb R. 1993. Cell transplantation as an experimental treatment for Duchenne muscular dystrophy. Cell Transplant 2:485-505.
68. Law PK, Goodwin TG, Fang Q, Hall TL, Quinley T, Vastagh G, Duggirala V, Larkin C, Florendo JA, Li L, Jackson T, Yoo TJ, Chase N, Neel M, Krahn T, Holcomb R. 1997. First human myoblast transfer therapy continues to show dystrophin after 6 years. Cell Transplant 6:95-100.
69. Lipton BH, Schultz E. 1979. Developmental fate of skeletal muscle satellite cells. Science 205:1292-1294.
70. Mantegazza R, Hughes SM, Mitchell D, Travis M, Blau HM, Steinman L. 1991. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 41:1128-1132.
71. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk S, Besson S, McAndrew PE, Rice R, Nagaraja H, Stephens R, Lantry L, Morris GE, Burghes AHM. 1995. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333:832-838.
72. Merly F, Huard C, Asselin I, Robbins PD, Tremblay JP. 1998. Anti-inflammatory effect of transforming growth factor-beta1 in myoblast transplantation. Transplantation 65:793-799.
73. Michaelis D, Goebels N, Hohlfeld R. 1993. Constitutive and cytokinie-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143:1142-1149.
74. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Yu P, Lanctot AM, Greco CM, Steiman L, Blau HM. 1997. Myoblast implantation in Duchenne Muscular Dystrophy: the San Francisco Study. Muscle Nerve 20:469-478.
75. Moisset P-A, Gagnon Y, Karpati G, Tremblay JP. 1998a. Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts. Gene Ther 5:1340-1346.
76. Moisset P-A, Skuk D, Asselin I, Goulet M, Roy B, Karpati G, Tremblay JP. 1998b. Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene. Biochem Biophys Res Commun 247:94-99.
77. Morgan JE, Coulton GR, Partridge TA. 1987. Muscle precursor cells invade and repopulate freeze-killed muscles. J Muscle Res Cell Motil 8:386-396.
78. Morgan JE, Hoffman EP, Partridge TA. 1990. Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111:2437-2449.
79. Morgan JE, Pagel CN, Sherratt T, Partridge TA. 1993. Long-term persistence and migration of myogenic cells injected into preirradiated muscles of mdx mice. J Neurol Sci 115:191-200.
80. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. 1996. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98:2512-2523.
81. Neu AM, Furth SL, Case BW, Wise B, Colombani PM, Fivush BA. 1997. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). Clin Transplant 11:412-414.
82. Neumeyer AM, DiGregorio DM, Brown RH. 1992. Arterial delivery of myoblasts to skeletal muscle. Neurology 42:2258-2262.
83. Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP, Pegoraro E, Hunter RG, Munsat TL, Brown RH. 1998. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology 51:589-592.
84. Ohtsuka Y, Udaka K, Yamashiro Y, Yagita H, Okumura K. 1998. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implications for gene therapy. J Immunol 160:4635-4640.
85. Olszewski WL, Poreda E, Jasklowska-Englisz M, Interewicz B. 1998. Hepatocyte transplantation: granulocytes and mononuclear cells recognize the surface of isolated autologous hepatocytes as non-self and destroy them. Transpl Int 11(Suppl 1):S367-371.
86. Partridge T, Beauchamp J, Morgan J, Tremblay JP, Huard J, Watt D, Wernig A, Irintchev A, Grounds M, Springer ML, Bartlett RJ, Mendell J, Vilquin J-T, Bower JJ. 1997. Meeting of the Cell Transplantation Society in Miami [letter; comment]. Cell Transplant 6:195-196.
87. Partridge T, Lu QL, Morris G, Hoffman E. 1998. Is myoblast transplantation effective? Nat Med 4:1208-1209.
88. Partridge TA, Grounds M, Sloper JC. 1978. Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature 273:306-308.
89. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. 1989. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337:176-179.
90. Pavlath GK, Rando TA, Blau HM. 1994. Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers. J Cell Biol 127:1923-1932.
91. Petrof BJ. 1998. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol Cell Biochem 179:111-123.
92. Phillips GD, Hoffman JR, Knighton DR. 1990. Migration of myogenic cells in the rat extensor digitorum longus muscle studied with a split autograft model. Cell Tissue Res 262:81-88.
93. Ponder BA.J, Wilkinson MM, Wood M, Westwood JH. 1983. Immunohistochemical demonstration of H2 antigens in mouse tissue sections. J Histochem Cytochem 31:911-19.
94. Qu Z, Balkir L, van Deutekom JC.T, Robbins PD, Pruchnic R, Huard J. 1998. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142:1257-1267.
95. Rando TA, Pavlath GK, Blau HM. 1995. The fate of myoblasts following transplantation into mature muscle. Exp Cell Res 220:383-389.
96. Robinson SW, Cho PW, Levitsky HI, Olson JL, Hruban RH, Acker MA, Kessler PD. 1996. Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. Cell Transplant 5:77-91.
97. Roman M, Axelrod JH, Dai Y, Naviaux RK, Friedmann T, Verma IM. 1992. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet 18:247-258.
98. Roy R, Dansereau G, Tremblay JP, Belles-Isles M, Labrecque C, Bouchard JP. 1991. Major histocompatibility complex (MHC) antigens expression on human myoblasts. Transplant Proc 23:799-801.
99. Roy R, Tremblay JP, Huard J, Richards CL, Malouin F, Bouchard JP. 1993. Antibody formation after myoblast transplantation in Duchenne dystrophic patients, donor HLA compatible. Transplant Proc 25:995-997.
100. Satoh A, Labrecque C, Tremblay JP. 1992. Myotubes can be formed within implanted adipose tissue. Transplant Proc 24:3017-3019.
101. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. 1999. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 5:97-100.
102. Simonson GD, Groskreutz DJ, Gorman CM, MacDonald MJ. 1996. Synthesis and processing of genetically modified human proinsulin by rat myoblasts primary cultures. Hum Gene Ther 7:71-78.
103. Skuk D, Tremblay JP. 1998. Complement deposition and cell death after myoblast transplantation. Cell Transplant 7:427-434.
104. Skuk D, Furling D, Bouchard J-P, Goulet M, Roy B, Lacroix Y, Vilquin J-T, Tremblay JP, Puymirat J. 1999a. Transplantation of human myoblasts in SCID mice as a potential muscular model for myotonic dystrophy. J Neuropathol Exp Neurol 58:921-931.
105. Skuk D, Roy B, Goulet M, Tremblay JP. 1999b. Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp Neurol 155:1-9.
106. Shuk D, Goulet M, Roy B, Tremblay JP. In press. Myoblast transplantation in whole muscle of non-human primates. J Neuropathol Exp.
107. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE. 1998. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 4:929-933.
108. Taylor DA, Silvestry SC, Bishop SP, Annex BH, Lilly RE, Glower DD, Kraus WE. 1997. Delivery of primary autologous skeletal myoblasts into rabbit heart by coronary infusion: a potential approach to myocardial repair. Proc Assoc Am Physicians 109:245-253.
109. Thompson L. 1992a. Cell-transplant results under fire. Science 257: 472-474.
110. Thompson L. 1992b. Researchers call for time out on cell-transplant research. Science 257:738.
111. Thomson AW. 1990. Interspecies comparison of the immunosuppressive efficacy and safety of FK506. Transplant Proc 22(Suppl 1):100-105.
112. Tremblay JP, Bouchard JP, Théau D, Cottrell F, Collin H, Tremblay M, Richards CL, Malouin F, Tomé F, Fardeau M. 1993a. Myoblast transplantation between monozygotic twin girls which are carriers of Duchenne muscular dystrophy. Neuromusc Disord 3:583-593.
113. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, Richards CL. 1993b. Results of a triple blind clinical study of myoblast transplantations without immunosuppresive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2:99-112.
114. Uchida K, Tominaga Y, Haba T, Katayama A, Ichimori T, Yamada K, Hibi Y, Uemura O, Morozumi K, Takagi H. 1998. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. Transplant Proc 30:1276-1278.
115. Vaidya TB, Rhodes SJ, Moore JL, Sherman DA, Konieczny SF, Taparowsky EJ. 1992. Isolation and structural analysis of the rat MyoD gene. Gene 116:223-230.
116. Valentine BA, Cooper BJ, Cummings JF. and de Lahunta A 1990. Canine X-linked muscular dystrophy: morphologic lesions. J Neurol Sci 97:1-23.
117. Van Meter CH. Jr, Claycomb WC, Delcarpio JB, Smith DM, de Gruiter H, Smart F, Ochsner JL. 1995. Myoblast transplantation in the porcine model: a potential technique for myocardial repair. J Thorac Cardiovasc Surg 110:1442-1448.
118. Vilquin J-T, Asselin I, Guérette B, Kinoshita I, Lille S, Roy R, Tremblay JP. 1994. Myoblast allotransplantation in mice: the degree of success varies depending on the efficacy of various immunosuppressive treatments. Transplant Proc 26:3372-3373.
119. Vilquin J-T, Asselin I, Guérette B, Kinoshita I, Lille S, Roy R, Tremblay JP. 1995a. Successful myoblast allotransplantation in mdx mice using rapamycin. Transplantation 59:422-449.
120. Vilquin J-T, Guérette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay JP. 1995b. FK506 immunosuppression to control the immune reactions triggered by the first generation adenovirus-mediated gene transfer. Hum Gene Ther 6:1391-1401.
121. Vilquin J-T, Kinoshita I, Roy R, Tremblay JP. 1995c. Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Neuromusc Disord 5:511-517.
122. Vilquin J-T, Wagner E, Kinoshita I, Roy R, Tremblay JP. 1995d. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 131:975-988.
123. Vilquin J-T, Brussee V, Asselin I, Kinoshita I, Gingras M, Tremblay JP. 1998. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 21:567-576.
124. Wang JM, Zheng H, Blaivas M, Kurachi K. 1997. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood 90:1075-1082.
125. Watt DJ. 1982. Factors which affect the fusion of allogeneic muscle precursor in vivo. Neuropathol Appl Neurobiol 8:135-147.
126. Watt DJ, Partridge TA, Sloper JG. 1981. Cyclosporin a as a means of preventing rejection of skeletal muscle allografts in mice. Transplantation 31:266-271.
127. Watt DJ, Morgan JE, Partridge TA. 1984. Use of monuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve 1984;7:741-750.
128. Webster C, Blau HM. 1990. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet 16:557-565.
129. Wernig A, Irintchev A, Lange G. 1995. Functional effects of myoblast implantation into histoincompatible mice with or without immunosuppression. J Physiol (Lond) 484.2:493-504.
130. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. 1996. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 15:1734-1741.
131. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4441.
132. Yao SN, Kurachi K. 1993. Implanted myoblasts not only fuse with myofibers but also survive as muscle precursor cells. J Cell Sci 105:957-963.